Atara Biotherapeutics Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Atara Biotherapeutics (NASDAQ:ATRA) reported Q4 sales of $7.55 million. Earnings fell to a loss of $93.35 million, resulting in a 10.26% decrease from last quarter.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows.
36 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 98 companies set new 52-week lows.
Atara Biotherapeutics Q4 EPS $(0.96) Misses $(0.69) Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(0.69) by 39.13 percent. This is a 1.05 percent decrease over losses of $(0.95) per share
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
